Drug General Information
Drug ID	D08EYQ
Former ID	DIB011613
Drug Name	ORE-1001
Synonyms	GL-1001; ACE2 enzyme inhibitor (inflammatory bowel disease), Ore Pharmaceuticals
Indication	Diabetes [ICD9: 253.5, 588.1; ICD10:E23.2, N25.1]		Phase 1/2	[1]
Company	Millennium Pharmaceuticals Inc
Structure		Download 2D MOL 3D MOL
Canonical SMILES	n1(c(C[C@H](N[C@@H](CC(C)C)C(=O)O)C(=O)O)cnc1)Cc1cc(cc(<br />c1)Cl)Cl
CAS Number	CAS 305335-31-3
Target and Pathway
Target(s)	Recombinant human angiotensin converting enzyme 2	Target Info	Inhibitor	[2]
KEGG Pathway	Renin-angiotensin system
	Protein digestion and absorption
Reactome	Metabolism of Angiotensinogen to Angiotensins
WikiPathways	ACE Inhibitor Pathway
	Metabolism of Angiotensinogen to Angiotensins
References
REF 1	ClinicalTrials.gov (NCT01039597) Safety and Activity of ORE1001 in Subjects With Ulcerative Colitis. U.S. National Institutes of Health.
REF 2	Effects of the ACE2 inhibitor GL1001 on acute dextran sodium sulfate-induced colitis in mice. Inflamm Res. 2009 Nov;58(11):819-27.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.